Recently, much research interest has been directed to demonstrating a possible biological basis to obsessive compulsive disorder. In particular, dys-regulation in brain serotonin is suggested to be important. Two cases are described in which fenfluramine, a presynaptic 5 HT-releasing agent and 5HT-reuptake inhibitor was used to augment clomipramine treatment for OCD.
References
1.
KarnoMGoldingJMSorensonMA. The epidemiology of obsessive-compulsive disorder in five US communities. Archives of General Psychiatry1988; 45: 1094–1099.
2.
InselTRMurphyDL. The psychopharmacological treatment of obsessive compulsive disorder: A review. Journal of Clinical Psychopharmacology1981; 1: 304–311.
3.
HollanderESchiffmanECohenBRivera-SteinMARosenWGormanJMFyerAJPappLLiebowitzMR. Signs of central nervous system dysfunction in obsessive compulsive disorder. Archives of General Psychiatry1990; 47: 27–32.
4.
LuxenbergJSSwedoSEFlamentMFFriedlandRPRapoportJRapoportSI. Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative X-ray computed tomography. American Journal of Psychiatry1988; 149: 1089–1093.
5.
BaxterLRSchwartzJMGuzeBHBergmanKSzubaMP. PET imaging in obsessive compulsive disorder with and without depression. Journal of Clinical Psychiatry1990; 51(Suppl): 61–69.
6.
ZoharJMuellerEAInselTRZohar-KadoughRCMurphyDL. Serotonergic responsivity in obsessive-compulsive disorder: Comparison of patients and healthy controls. Archives of General Psychiatry1987; 44: 946–951.
7.
HollanderEFayMCohenBCampeasRGormanJMLiebowitzMR. Serotonergic and noradrenergic sensitivity in obsessive compulsive disorder: Behavioural findings. American Journal of Psychiatry1988; 145: 1015–1017.
8.
BenkelfatCMurphyDLZoharJHillJLGroverGInselTR. Clomipramine in obsessive-compulsive disorder. Archives of General Psychiatry1989; 46: 23–28.
9.
TrulsonMEJacobsBL. Behavioural evidence for rapid release of CNS serotonin by PCA and fenfluramine. European Journal of Pharmacology1976; 36: 149–154.
10.
GarattinisKCacciaSMenniniT. The mechanism of action of fenfluramine. Postgraduate Medical Journal1975; 5: 27–34.
11.
HewlettWAAgrasWSBermanS. Fenfluramine stimulation of hormone release in obsessive compulsive disorder. Soc. Neurosci19891122 (abstract 449.4).
12.
MurphyDLZoharJBenkelfatCPatoMTPigottTAInselTR. Obsessive-compulsive disorder as a 5HT subsystem-related behavioural disorder. British Journal of Psychiatry1989; 155(Suppl 8) 15–24.
13.
JenikeMAButtolphLBaerLRicciardiJHollandA. Open trial of fluoxetine in obsessive compulsive disorder. American Journal of Psychiatry1989; 146: 909–911.
14.
LibeowitzMRHollanderESchneierFCampeasRHattererJPappLFairbanksJSandbergDDaviesSSteinM. Fluoxetine treatment of obsessive-compulsive disorder: An open clinical trial. Journal of Clinical Psychopharmacology1989; 9: 423–427.
15.
GoodmanWKPriceLHRasmussenSADelgadoPLHeningerGRCharneyDS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double blind comparison with placebo. Archives of General Psychiatry1989; 46: 36–44.
16.
HollanderEde CariaCMSchneierFRSchneierHALiebowitzMRKleinDF. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Journal of Clinical Psychiatry1990; 51: 119–123.
17.
InvernizziRBeretteraCGarattinSSamaninR. D- and I-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. European Journal of Pharmacology1986; 120: 9–14.
